Cargando…
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
Omicron SARS-CoV-2 variants escape vaccine-induced neutralizing antibodies and cause nearly all current COVID-19 cases. Here, we compared the efficacy of three booster vaccines against Omicron BA.5 challenge in rhesus macaques: mRNA-1273, the Novavax ancestral spike protein vaccine (NVX-CoV2373), or...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451060/ https://www.ncbi.nlm.nih.gov/pubmed/37191508 http://dx.doi.org/10.1126/sciimmunol.adg7015 |
_version_ | 1785095344570236928 |
---|---|
author | Routhu, Nanda Kishore Stampfer, Samuel David Lai, Lilin Akhtar, Akil Tong, Xin Yuan, Dansu Chicz, Taras M. McNamara, Ryan P. Jakkala, Kishor Davis-Gardner, Meredith E. St Pierre, E. Lovisa Smith, Brandon Green, Kristyn Moore Golden, Nadia Picou, Breanna Jean, Sherrie M. Wood, Jennifer Cohen, Joyce Moore, Ian N. Patel, Nita Guebre-Xabier, Mimi Smith, Gale Glenn, Greg Kozlowski, Pamela A. Alter, Galit Ahmed, Rafi Suthar, Mehul S. Amara, Rama Rao |
author_facet | Routhu, Nanda Kishore Stampfer, Samuel David Lai, Lilin Akhtar, Akil Tong, Xin Yuan, Dansu Chicz, Taras M. McNamara, Ryan P. Jakkala, Kishor Davis-Gardner, Meredith E. St Pierre, E. Lovisa Smith, Brandon Green, Kristyn Moore Golden, Nadia Picou, Breanna Jean, Sherrie M. Wood, Jennifer Cohen, Joyce Moore, Ian N. Patel, Nita Guebre-Xabier, Mimi Smith, Gale Glenn, Greg Kozlowski, Pamela A. Alter, Galit Ahmed, Rafi Suthar, Mehul S. Amara, Rama Rao |
author_sort | Routhu, Nanda Kishore |
collection | PubMed |
description | Omicron SARS-CoV-2 variants escape vaccine-induced neutralizing antibodies and cause nearly all current COVID-19 cases. Here, we compared the efficacy of three booster vaccines against Omicron BA.5 challenge in rhesus macaques: mRNA-1273, the Novavax ancestral spike protein vaccine (NVX-CoV2373), or Omicron BA.1 spike protein version (NVX-CoV2515). All three booster vaccines induced a strong BA.1 cross-reactive binding antibody and changed immunoglobulin G dominance from IgG1 to IgG4 in the serum. All three booster vaccines also induced strong and comparable neutralizing antibody responses against multiple variants of concern, including BA.5 and BQ.1.1, along with long-lived plasma cells in the bone marrow. The ratio of BA.1 to WA-1 spike-specific antibody-secreting cells in the blood was higher in NVX-CoV2515 animals compared to NVX-CoV2373 animals, suggesting a better recall of BA.1 specific memory B cells by the BA.1 spike-specific vaccine compared to the ancestral spike-specific vaccine. Further, all three booster vaccines induced low levels of spike-specific CD4 but not CD8 T cell responses in the blood. Following challenge with SARS-CoV-2 BA.5 variant, all three vaccines showed strong protection in the lungs and controlled virus replication in the nasopharynx. In addition, both Novavax vaccines blunted viral replication in nasopharynx at day 2. The protection against SARS-CoV-2 BA.5 infection in the upper respiratory airways correlated with binding, neutralizing, and ADNP activities of the serum antibody. These data have important implications for COVID-19 vaccine development, as vaccines that lower nasopharyngeal virus may help to reduce transmission. |
format | Online Article Text |
id | pubmed-10451060 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-104510602023-09-11 Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates Routhu, Nanda Kishore Stampfer, Samuel David Lai, Lilin Akhtar, Akil Tong, Xin Yuan, Dansu Chicz, Taras M. McNamara, Ryan P. Jakkala, Kishor Davis-Gardner, Meredith E. St Pierre, E. Lovisa Smith, Brandon Green, Kristyn Moore Golden, Nadia Picou, Breanna Jean, Sherrie M. Wood, Jennifer Cohen, Joyce Moore, Ian N. Patel, Nita Guebre-Xabier, Mimi Smith, Gale Glenn, Greg Kozlowski, Pamela A. Alter, Galit Ahmed, Rafi Suthar, Mehul S. Amara, Rama Rao Sci Immunol Research Articles Omicron SARS-CoV-2 variants escape vaccine-induced neutralizing antibodies and cause nearly all current COVID-19 cases. Here, we compared the efficacy of three booster vaccines against Omicron BA.5 challenge in rhesus macaques: mRNA-1273, the Novavax ancestral spike protein vaccine (NVX-CoV2373), or Omicron BA.1 spike protein version (NVX-CoV2515). All three booster vaccines induced a strong BA.1 cross-reactive binding antibody and changed immunoglobulin G dominance from IgG1 to IgG4 in the serum. All three booster vaccines also induced strong and comparable neutralizing antibody responses against multiple variants of concern, including BA.5 and BQ.1.1, along with long-lived plasma cells in the bone marrow. The ratio of BA.1 to WA-1 spike-specific antibody-secreting cells in the blood was higher in NVX-CoV2515 animals compared to NVX-CoV2373 animals, suggesting a better recall of BA.1 specific memory B cells by the BA.1 spike-specific vaccine compared to the ancestral spike-specific vaccine. Further, all three booster vaccines induced low levels of spike-specific CD4 but not CD8 T cell responses in the blood. Following challenge with SARS-CoV-2 BA.5 variant, all three vaccines showed strong protection in the lungs and controlled virus replication in the nasopharynx. In addition, both Novavax vaccines blunted viral replication in nasopharynx at day 2. The protection against SARS-CoV-2 BA.5 infection in the upper respiratory airways correlated with binding, neutralizing, and ADNP activities of the serum antibody. These data have important implications for COVID-19 vaccine development, as vaccines that lower nasopharyngeal virus may help to reduce transmission. American Association for the Advancement of Science 2023-05-16 /pmc/articles/PMC10451060/ /pubmed/37191508 http://dx.doi.org/10.1126/sciimmunol.adg7015 Text en Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Routhu, Nanda Kishore Stampfer, Samuel David Lai, Lilin Akhtar, Akil Tong, Xin Yuan, Dansu Chicz, Taras M. McNamara, Ryan P. Jakkala, Kishor Davis-Gardner, Meredith E. St Pierre, E. Lovisa Smith, Brandon Green, Kristyn Moore Golden, Nadia Picou, Breanna Jean, Sherrie M. Wood, Jennifer Cohen, Joyce Moore, Ian N. Patel, Nita Guebre-Xabier, Mimi Smith, Gale Glenn, Greg Kozlowski, Pamela A. Alter, Galit Ahmed, Rafi Suthar, Mehul S. Amara, Rama Rao Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates |
title | Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates |
title_full | Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates |
title_fullStr | Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates |
title_full_unstemmed | Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates |
title_short | Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates |
title_sort | efficacy of mrna-1273 and novavax ancestral or ba.1 spike booster vaccines against sars-cov-2 ba.5 infection in non-human primates |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451060/ https://www.ncbi.nlm.nih.gov/pubmed/37191508 http://dx.doi.org/10.1126/sciimmunol.adg7015 |
work_keys_str_mv | AT routhunandakishore efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT stampfersamueldavid efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT laililin efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT akhtarakil efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT tongxin efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT yuandansu efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT chicztarasm efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT mcnamararyanp efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT jakkalakishor efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT davisgardnermeredithe efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT stpierreelovisa efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT smithbrandon efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT greenkristynmoore efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT goldennadia efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT picoubreanna efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT jeansherriem efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT woodjennifer efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT cohenjoyce efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT mooreiann efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT patelnita efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT guebrexabiermimi efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT smithgale efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT glenngreg efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT kozlowskipamelaa efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT altergalit efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT ahmedrafi efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT sutharmehuls efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates AT amararamarao efficacyofmrna1273andnovavaxancestralorba1spikeboostervaccinesagainstsarscov2ba5infectioninnonhumanprimates |